On the stock market since 2018, it operates in the world of health and science. It has 130 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades below its recent peak — about 14% off the top. A pullback, not a collapse.
The average analyst price target is $63.75 — 60% above today’s price.
A loss of $230.0M against $0 in annual sales.
This stock swings about 2.2 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, KOD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: KOD is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (42/100) says the stock isn’t cheap.